Abstract: Provided is an interfering RNA targeting Janus kinase 1 (JAK1). The interfering RNA can reduce the expression of JAK1 and further inhibit the activation of a JAK/STAT signaling pathway, thereby achieving the purpose of treating a JAK/STAT signaling pathway dysregulation-associated disease. Further provided is a lipid nanoparticle drug containing the interfering RNA for use in treating a JAK/STAT signaling pathway dysregulation-associated disease. Further provided is an antibody-nucleic acid drug conjugate containing the interfering RNA for use in treating a JAK/STAT signaling pathway dysregulation-associated disease.

Abstract: The present invention provides an interfering RNA targeting TOP1 gene. The interfering RNA can reduce the expression of TOP1, thereby treating a disease related to TOP1 expression. The present invention further provides a lipid nanoparticle drug comprising the interfering RNA for treating a disease related to TOP1 expression. The present invention further provides an antibody-nucleic acid conjugate drug comprising the interfering RNA for treating a disease related to TOP1 expression.

Abstract: The present invention discloses an interfering RNA for inhibiting PCSK9 gene and use thereof. The interfering RNA comprises a nucleotide sequence set forth in any one or two or more of SEQ ID NOs: 1-40, 73-96. The interfering RNA of the present invention can better target and silence hepatic PCSK9 mRNA, reduce the protein level of PCSK9, enhance LDL-C metabolism, and reduce serum cholesterol, providing a solid technical foundation for the development of siRNA medicaments for the prevention, treatment, and symptom alleviation of PCSK9 gene-mediated diseases.

Abstract: Disclosed in the present invention are a targeting antibody-polyethylene glycol-siRNA drug conjugate, and a preparation method therefor and the use thereof. The ligand drug conjugate has a structure as represented by general formula (I). Further disclosed in the present invention is that a polyethylene glycol derivative having excellent biocompatibility is used as a linker, and targeted delivery of specific CFD-siRNA is achieved using binding specificity of an antibody and an antigen. The drug conjugate has high biocompatibility and minor side effects, can effectively inhibit CFD gene expression, and provides a new choice for preventing or treating CFD-related diseases.

Abstract: A new typepolyethylene glycol lipid and the use thereof. The lipid is free of in-vivo cleavable bonds, and can deliver a bioactive substance to a target cell or organ more stably. In addition, the new typepolyethylene glycol lipid can be positively charged in a specific pH environment, and can more easily form stable particles with the bioactive substance, so that the bioactive substance plays a role in the target cell or organ.

Abstract: Provided are an ionizable lipid compound of formula I for nucleic acid delivery and an LNP composition thereof, which can efficiency and stably deliver a biologically active substance to a target cell or an organ. The mRNA LNP prepared by using the lipid compound as a cationic lipid has better stability and transfection efficiency, and can cause a higher specific antibody response in an experimental animal body.

Abstract: Provided are a polyol-modified lipid compound, a preparation method therefor and an application thereof. The lipid compound and lipid nanoparticles prepared therefrom can target and effectively deliver biologically active substances to target cells and sites, and efficiently achieve pharmacological effects of the biologically active substances. In addition, the lipid compound has a singular molecular weight, which is beneficial for controlling differences between batches, improving the stability of finished drugs, and reducing immunogenicity; it is expected to be used for the development and application of related drugs.

Abstract: The disclosure discloses a linker compound, a polyethylene glycol-linker conjugate and a derivative thereof, and a polyethylene glycol-linker-drug conjugate. The linker compound as well as the conjugate thereof with the polyethylene glycol and the derivative thereof may be used for modifying a drug, and a modification reaction is simple and easy to carry out. Moreover, a reaction yield is high, and an application range of the modified drug is wide. The modified drugs gradually degrade from a chain of the conjugate in vivo, and may stay in a lesion (such as a cancer site) for a longer period of time, achieving purposes of sustained and controlled release, reducing an administration frequency, and greatly improving a bioavailability of the drug and a patient compliance.

Abstract: An antitumor pharmaceutical composition and an application thereof. Active ingredients of the antitumor pharmaceutical composition contain a polyethylene glycol-modified camptothecin derivative (in particular, polyethylene glycol-modified irinotecan) and temozolomide. It is proved by means of animal experiments that the administration of polyethylene glycol-modified camptothecin derivative (in particular, polyethylene glycol-modified irinotecan) and temozolomide in combination has an extremely strong treatment effect on tumors (such as neuroblastoma), and the tumor inhibition rate can reach 98% and is significantly superior to that of a monotherapy group; thus, the provided antitumor pharmaceutical composition has better application prospects for treatment of tumors.

Abstract: The present invention discloses a method for preparing a PEGylated biomolecule with controllable binding sites, comprising: (1) PEGylating a biomolecule; (2) binding a barrier to at least one binding site in the PEGylated biomolecule; (3) separating the PEGylated biomolecule not bound to the barrier; and (4) separating the barrier and the PEGylated biomolecule bound thereto. In another aspect, the present invention discloses a method for preparing a PEGylated IL-2 with controllable binding sites, comprising: (1) PEGylating to couple a PEG with IL-2; (2) binding the PEGylated IL-2 to an IL-2? receptor; (3) separating the PEGylated IL-2 not bound to the IL-2? receptor; and (4) separating the IL-2? receptor and the PEGylated IL-2 bound thereto. By regulating the binding sites of IL-2, only 1 or 2 PEGs are added during PEGylation.

Abstract: The present invention discloses a preparation method for a disubstituted PEGylated interleukin 2, which comprises the steps of: (1) PEGylating IL-2 to obtain a crude product of a PEGylated interleukin; (2) performing gel chromatography filtration to remove free interleukin 2 from the crude product; (3) performing affinity chromatography on the product in the step (2) by means of an ? receptor column, and collecting a flow-through peak component and an elution peak component; (4) performing ion exchange separation on the flow-through peak component and the elution peak component in the step (3); and (5) collecting components of the disubstituted PEGylated interleukin 2.

Abstract: The present invention discloses a method of preparing PEGylated biomolecules having controllable binding sites, including the following steps: (1) binding a blocker to a biomolecule; (2) PEGylating the biomolecule; and (3) separating the blocker from the biomolecule. In another aspect, the present invention discloses a method for preparing PEGylated IL-2 having controllable binding sites, including the following steps: (1) binding IL-2 to an IL-2? receptor, closing the a binding site of the IL-2; (2) PEGylating, coupling PEG with the IL-2; and (3) separating the IL-2 from the IL-2? receptor. By regulating IL-2 binding sites and a PEGylation process only adding one or two polyethylene glycols, the IL-2 is caused to selectively bind to an IL-2R ??-type receptor.

Abstract: The disclosure discloses a linker compound, a polyethylene glycol-linker conjugate and a derivative thereof, and a polyethylene glycol-linker-drug conjugate. The linker compound as well as the conjugate thereof with the polyethylene glycol and the derivative thereof may be used for modifying a drug, and a modification reaction is simple and easy to carry out. Moreover, a reaction yield is high, and an application range of the modified drug is wide. The modified drugs gradually degrade from a chain of the conjugate in vivo, and may stay in a lesion (such as a cancer site) for a longer period of time, achieving purposes of sustained and controlled release, reducing an administration frequency, and greatly improving a bioavailability of the drug and a patient compliance.

Abstract: A method for a near-field communication (NFC) tag to perform NFC and wireless power transfer (WPT) with an NFC reader, the NFC tag having an antenna resonant circuit, of which a quality factor (Q-factor) is no lower than 50 in a high-Q mode of the NFC tag, and no higher than 25 in a low-Q mode of the NFC tag. The method includes continuously preforming steps of detecting an NFC radio frequency (RF) field generated by the NFC reader, measuring strength of the NFC RF field, operating in the high-Q mode for the WPT upon determining that the strength of the NFC RF field is larger than a predetermined threshold, operating in the low-Q mode for the NFC upon determining that the strength of the NFC RF field is smaller than the predetermined threshold, and transmitting a response back to the NFC reader.

Abstract: A device for near-field communication (NFC) and wireless power reception (WPR) using a magnetic field. The device has an antenna resonant circuit. The antenna resonant circuit includes an antenna for magnetic flux of the magnetic field to flow therethrough, to thereby receive a NFC signal during the NFC and receive wireless power during the WPR, and a multi-Q antenna matching circuit configured to adjust an impedance of the antenna to thereby adjust a quality factor (Q-factor) of the antenna resonant circuit. The multi-Q antenna matching circuit is configured to switch between a high-Q mode for the WPR and a low-Q mode for the NFC, based on whether strength of the magnetic field is larger than a predetermined threshold. The device may also include two separate antenna resonant circuits, of which the Q-factors are respectively no higher than 25 and no lower than 50.

Abstract: A device for near-field communication (NFC) and wireless power transfer. The device has an antenna resonant circuit that includes an antenna for transmitting and receiving signals, a multi-Q antenna matching circuit for adjusting a Q-factor of the antenna resonant circuit, and an antenna driver for driving the antenna through the multi-Q antenna matching circuit. The device also includes a microcontroller (MCU) configured to control the multi-Q antenna matching circuit to switch between a high-Q mode for wireless power transfer and a low-Q mode for NFC.

Abstract: A device for near-field communication (NFC) and wireless power transfer. The device has an antenna resonant circuit that includes an antenna for transmitting and receiving signals, a multi-Q antenna matching circuit for adjusting a Q-factor of the antenna resonant circuit, and an antenna driver for driving the antenna through the multi-Q antenna matching circuit. The device also includes a microcontroller (MCU) configured to control the multi-Q antenna matching circuit to switch between a high-Q mode for wireless power transfer and a low-Q mode for NFC.

Abstract: A device for near-field communication (NFC) and wireless power reception (WPR) using a magnetic field. The device has an antenna resonant circuit. The antenna resonant circuit includes an antenna for magnetic flux of the magnetic field to flow therethrough, to thereby receive a NFC signal during the NFC and receive wireless power during the WPR, and a multi-Q antenna matching circuit configured to adjust an impedance of the antenna to thereby adjust a quality factor (Q-factor) of the antenna resonant circuit. The multi-Q antenna matching circuit is configured to switch between a high-Q mode for the WPR and a low-Q mode for the NFC, based on whether strength of the magnetic field is larger than a predetermined threshold. The device may also include two separate antenna resonant circuits, of which the Q-factors are respectively no higher than 25 and no lower than 50.

Abstract: A method for a near-field communication (NFC) tag to perform NFC and wireless power transfer (WPT) with an NFC reader, the NFC tag having an antenna resonant circuit, of which a quality factor (Q-factor) is no lower than 50 in a high-Q mode of the NFC tag, and no higher than 25 in a low-Q mode of the NFC tag. The method includes continuously preforming steps of detecting an NFC radio frequency (RF) field generated by the NFC reader, measuring strength of the NFC RF field, operating in the high-Q mode for the WPT upon determining that the strength of the NFC RF field is larger than a predetermined threshold, operating in the low-Q mode for the NFC upon determining that the strength of the NFC RF field is smaller than the predetermined threshold, and transmitting a response back to the NFC reader.